Pipeline – Ixazomib

Overview¹

- Ixazomib is an oral proteasome inhibitor that can be administered weekly at a fixed dose

Mechanism of Action^1-3

- Ixazomib blocks protein degradation in myeloma cells causing apoptosis and cell death via multiple mechanisms

- Proteasome inhibition has direct effects on both malignant plasma cells and the MM cell microenvironment through:

• Inhibition of cytokine secretion
• Suppression of adhesion molecule expression
• Inhibition of angiogenesis

Clinical Trials

The following are currently ongoing Takeda sponsored trials.

Study Name

A National, Prospective, Non-interventional Study of Ixazomib in Real World Clinical Practice (This Study is only recruiting in China).

Study Name

China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Study Name

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)

References

1. Ninlaro® [package insert]. Takeda Pharmaceutical Company Limited.

2. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034-2042. doi:10.1158/1535-7163.MCT-11-0433

3. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947-959. doi:10.1182/blood-2012-04-403733

Disclaimers

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov *Marketed products have received approval in one or more jurisdictions.